Literature DB >> 22487070

Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis.

Achuthan Sourianarayanane1, Galal El-Gazzaz, Juan R Sanabria, K V Narayanan Menon, Cristiano Quintini, Koji Hashimoto, Dympna Kelly, Bijan Eghtesad, Charles Miller, John Fung, Federico Aucejo.   

Abstract

OBJECTIVES: Liver transplantation (LT) in Milan Criteria (MC) hepatocellular carcinoma (HCC) has excellent outcomes. Pre-transplant loco-regional therapy (LRT) has been used to downstage HCC to meet the MC. However, its benefit in patients with a brief waiting time to transplant remains unclear. This study evaluated outcomes in patients with short waitlist times to LT for MC-compliant HCC.
METHODS: Patients undergoing LT for MC HCC at either of two transplant centres between 2002 and 2009 were retrospectively evaluated for outcome. Patients for whom post-transplant follow-up amounted to <12 months were excluded.
RESULTS: A total of 225 patients were included, 93 (41.3%) of whom received neoadjuvant LRT. The median waiting time to transplant was 48 days. Mean post-transplant follow-up was 32.2 months. Overall and disease-free survival at 1 year, 3 years and 5 years were 93.1%, 82.4% and 72.6%, and 91.3%, 79.3% and 70.6%, respectively. There was no difference in overall (P= 0.94) and disease-free survival (P= 0.94) between groups who received and did not receive pre-LT LRT. There were also no disparities in survival or tumour recurrence among categories of patients (with single tumours measuring <3 cm, with single tumours measuring 3-5 cm, with multiple tumours).
CONCLUSIONS: Loco-regional therapy followed by rapid transplantation in MC HCC appears not to have an impact on post-transplant outcome.
© 2012 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2012        PMID: 22487070      PMCID: PMC3384852          DOI: 10.1111/j.1477-2574.2012.00453.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  23 in total

1.  Impact of geographic disparity on liver allocation for hepatocellular cancer in the United States.

Authors:  Zakiyah Kadry; Eric W Schaefer; Tadahiro Uemura; Ali Riaz Shah; Ian Schreibman; Thomas R Riley
Journal:  J Hepatol       Date:  2011-10-23       Impact factor: 25.083

2.  Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma.

Authors:  Shimul A Shah; Jensen C C Tan; Ian D McGilvray; Mark S Cattral; Sean P Cleary; Gary A Levy; Paul D Greig; David R Grant
Journal:  Transplantation       Date:  2006-06-27       Impact factor: 4.939

3.  Correlation between the radiologic and histologic size of hepatocellular carcinoma in patients eligible for liver transplantation.

Authors:  G A Mejia; M A Gomez; J Serrano; I Garcia; M J Tamayo; F Pareja; J M Sousa; J M Pascacio; F Gavilan; J Castell; B Vargas; A Bernardos
Journal:  Transplant Proc       Date:  2006-06       Impact factor: 1.066

4.  Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma.

Authors:  Gunda Millonig; Ivo W Graziadei; Martin C Freund; Werner Jaschke; Sylvia Stadlmann; Ruth Ladurner; Raimund Margreiter; Wolfgang Vogel
Journal:  Liver Transpl       Date:  2007-02       Impact factor: 5.799

5.  Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence.

Authors:  Jeremy R Parfitt; Paul Marotta; Mohammed Alghamdi; William Wall; Anand Khakhar; Neville G Suskin; Douglas Quan; Vivian McAllister; Cam Ghent; Mark Levstik; Carolyn McLean; Subrata Chakrabarti; Bertha Garcia; David K Driman
Journal:  Liver Transpl       Date:  2007-04       Impact factor: 5.799

6.  Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time.

Authors:  Thomas Decaens; Françoise Roudot-Thoraval; Solange Hadni-Bresson; Carole Meyer; Jean Gugenheim; Francois Durand; Pierre-Henri Bernard; Olivier Boillot; Laurent Sulpice; Yvon Calmus; Jean Hardwigsen; Christian Ducerf; Georges-Philippe Pageaux; Sebastien Dharancy; Olivier Chazouilleres; Daniel Cherqui; Christophe Duvoux
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

7.  Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma.

Authors:  S D Chao; J P Roberts; M Farr; F Y Yao
Journal:  Am J Transplant       Date:  2007-04-08       Impact factor: 8.086

8.  A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.

Authors:  Francis Y Yao; Ryutaro Hirose; Jeanne M LaBerge; Timothy J Davern; Nathan M Bass; Robert K Kerlan; Raphael Merriman; Sandy Feng; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Liver Transpl       Date:  2005-12       Impact factor: 5.799

9.  Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era.

Authors:  Paige M Porrett; Heather Peterman; Mark Rosen; Seema Sonnad; Michael Soulen; James F Markmann; Abraham Shaked; Emma Furth; K Rajender Reddy; Kim Olthoff
Journal:  Liver Transpl       Date:  2006-04       Impact factor: 5.799

10.  Results of the first year of the new liver allocation plan.

Authors:  Richard B Freeman; Russell H Wiesner; Erick Edwards; Ann Harper; Robert Merion; Robert Wolfe
Journal:  Liver Transpl       Date:  2004-01       Impact factor: 5.799

View more
  4 in total

Review 1.  Bridging to liver transplantation in HCC patients.

Authors:  Dagmar Kollmann; Nazia Selzner; Markus Selzner
Journal:  Langenbecks Arch Surg       Date:  2017-07-28       Impact factor: 3.445

2.  Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?

Authors:  Dimitri Dorcaratto; Venkatesha Udupa; Niamh M Hogan; David P Brophy; Jeffrey W McCann; Donal Maguire; Justin Geoghegan; Colin P Cantwell; Emir Hoti
Journal:  Diagn Interv Radiol       Date:  2017 Nov-Dec       Impact factor: 2.630

Review 3.  Liver transplantation for hepatocellular carcinoma.

Authors:  Jerome Byam; John Renz; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2013-02       Impact factor: 7.293

4.  Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation.

Authors:  Wei Zhang; An-Hui Xu; Wei Wang; Yan-Hui Wu; Qian-Ling Sun; Chang Shu
Journal:  BMC Cancer       Date:  2019-11-05       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.